Extra Fluid Removal During Dialysis for People With Kidney Failure
Tests extra ultrafiltration to remove excess body fluid in adults on hemodialysis.
Key facts
- Who runs it
- University of Washington
- Where
- Seattle, United StatesSee the site
- Trial code
- Registry title
- Dry Weight Reduction Intervention Via Extra Ultrafiltration
- Status
- Recruiting
- People taking part
- 120 people, planned
- Started
- 10 Sept 2026
- Expected to end
- Nov 2030
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Ultrafiltration
- Record updated
- 30 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who have had hemodialysis three times a week for at least four weeks and may have too much fluid in the body.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- End stage kidney disease treated with in-center hemodialysis three times a week for at least four weeks, with suspected extra fluid.
- Earlier treatment
- At least four weeks of thrice weekly in-center hemodialysis. Not on dialysis for acute kidney injury.
- Biomarker or test result
- Either three pre-dialysis systolic blood pressures in a row of 140 mmHg or higher, or three in a row of 130-140 mmHg with at least two blood pressure medicines that can be tapered. Or a 12-item KM-KCCQ score below 75.
Main reasons for not taking part
- Planned switch to peritoneal or home dialysis within three months
- Fewer than 3 or four or more hemodialysis treatments per week
- Scheduled kidney transplant
- Major cardiovascular or bleeding event in the past 90 days
- Pre-dialysis systolic blood pressure below 100 mmHg
This trial only enrols participants on dialysis. The registry sentence this rests on: Receiving thrice weekly in-center hemodialysis treatments for end stage kidney disease for at least four weeks and clinical suspicion of volume excess based on either:
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Receiving thrice weekly in-center hemodialysis treatments for end stage kidney disease for at least four weeks and clinical suspicion of volume excess based on either:; Persistent hypertension defined by three consecutive pre-dialysis systolic blood pressures ≥140 mmHg or three consecutive pre-dialysis systolic blood pressures 130-140 mmHg plus use of at least two anti-hypertensive medications that can be tapered; OR; Symptoms of congestion defined by a 12-item Kidney Modified Kansas City Cardiomyopathy Questionnaire (KM-KCCQ) score <75
Who cannot take part
- Receiving hemodialysis treatments for acute kidney injury
- Receiving hemodialysis treatments for less than four weeks
- Scheduled kidney transplantation
- Major cardiovascular or bleeding event within previous 90 days
- Receiving chemotherapy or radiation treatment for cancer
- History of cirrhosis with ascites
- History of non-adherence with dialysis treatments
- Age <18 years
- Planned switch to peritoneal or home dialysis within next three months
- Current or planned incremental hemodialysis (less than 3 treatments per week)
- Current or planned intensive hemodialysis (four or more treatments per week)
- Inability to complete 24-hour ambulatory blood pressure measurement
- Wheelchair dependance or other inability to complete six-minute walk test
- Pre-dialysis systolic blood pressure <100 mmHg
- Scheduled use of midodrine with hemodialysis treatments
- Pregnancy
- Institutionalized
- Current or pending enrollment in hospice care
- Inappropriate for enrollment based on investigator or nephrologist discretion
Where in United States
- Northwest Kidney CentersSeattle, United StatesContact: Luisa Rios-AvilaTaking people
About the trial
What the trial wants to find out
Most patients who receive hemodialysis treatments have excess fluid in their body that has slowly built up over the course of kidney disease. This extra fluid is the main cause of high blood pressure in dialysis and leads to stress on the heart and lungs.that causes debilitating symptoms and frequent hospitalizations.
Read full original descriptionShow less
This trial will test whether a focused program of 4 or 8 weeks of extra ultrafiltration treatments can remove most of this extra fluid. We believe that getting rid of large amounts of extra fluid will result in sustained improvements in blood pressure and symptoms. Ultrafiltration is a gentler type of dialysis that removes fluid but does not clean the blood.
The 3 groups in the trial
- Ultrafiltration treatments for up to 4 weeksExisting treatment, for comparison
Two ultrafiltration treatments per week for up to 4 weeks; pharmacist guided tapering of blood pressure medications for up to 4 weeks; and regular thrice weekly hemodialysis treatments.
Treatment: Ultrafiltration
- Ultrafiltration treatments for up to 8 weeksExisting treatment, for comparison
Two ultrafiltration treatments per week for up to 8 weeks; pharmacist guided tapering of blood pressure medications for up to 8 weeks; and regular thrice weekly hemodialysis treatments.
Treatment: Ultrafiltration
- Control armNo study treatment, for comparison
Regular thrice weekly hemodialysis treatments.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Dry Weight Reduction Intervention Via Extra Ultrafiltration
- Plain-language title
- Extra Fluid Removal During Dialysis for People With Kidney FailureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 30 October 2026